Karen A. Flynn
Net Worth
Last updated:
What is Karen A. Flynn net worth?
The estimated net worth of Ms. Karen A. Flynn is at least $5,177,001 as of 10 Jan 2022. She has earned $577,001 from insider trading and has received compensation worth at least $4,600,000 in Catalent, Inc..
What is the salary of Karen A. Flynn?
Ms. Karen A. Flynn salary is $1,150,000 per year as Chief Commercial Officer in Catalent, Inc..
How old is Karen A. Flynn?
Ms. Karen A. Flynn is 62 years old, born in 1963.
What stocks does Karen A. Flynn currently own?
As insider, Ms. Karen A. Flynn owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Catalent, Inc. (CTLT) | Chief Commercial Officer | 33,223 | $0 | $0 |
What does Catalent, Inc. do?
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Karen A. Flynn insider trading
Catalent, Inc.
Ms. Karen A. Flynn has made 4 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently she sold 2,472 units of CTLT stock worth $288,334 on 10 Jan 2022.
The largest trade she's ever made was exercising 2,478 units of CTLT stock on 11 Jan 2021. As of 10 Jan 2022 she still owns at least 33,223 units of CTLT stock.
Catalent key executives
Catalent, Inc. executives and other stock owners filed with the SEC:
- Mr. Alessandro Maselli (53) Pres & Chief Operating Officer
- Mr. John R. Chiminski (61) Chairman & Chief Executive Officer
- Mr. Steven L. Fasman (62) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Thomas P. Castellano (45) Senior Vice President & Chief Financial Officer
- Ms. Karen A. Flynn (62) Chief Commercial Officer